LivaNova PLC (LIVN) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $72.92, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.5% away).
LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion, cannulae) and Neuromodulation (VNS Therapy for epilepsy and depression, plus OSA pipeline). Products are sold through direct sales and... Read more
Hold if already holding. Not a fresh buy at $72.92, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.5% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — LivaNova PLC
Latest news
- LivaNova (LIVN) Projected to Post Earnings on Wednesday - MarketBeat — MarketBeat neutral
- LivaNova PLC (LIVN) Shares Fall 3.3% -- GF Value Says Still Over - GuruFocus — GuruFocus neutral
- Earnings call transcript: LivaNova PLC beats Q1 2026 estimates, shares rise - Investing.com Canada — Investing.com Canada positive
- LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance — Yahoo Finance positive
- Earnings Flash (LIVN) LivaNova PLC Reports Q1 Revenue $362.3M, vs. FactSet Est of $346.1M - marketscreener.com — marketscreener.com positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $72.92, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (0.5% away). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $72.83 (-0.1%), stop $67.82 (−7.5%), A.R:R -0.3:1. Score 6.1/10, moderate confidence.
Take-profit target: $72.83 (-0.1% upside). Target $72.83 (-0.1%), stop $67.82 (−7.5%), A.R:R -0.3:1. Stop-loss: $67.82.
Analyst target reached - limited upside remaining; Near 52-week high (0.5% away).
LivaNova PLC trades at a P/E of 36.9 (forward 15.6). TrendMatrix value score: 6.0/10. Verdict: Hold.
17 analysts cover LIVN with a consensus score of 4.1/5. Average price target: $80.
What does LivaNova PLC do?LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators,...
LivaNova is a global medical technology company with two segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion, cannulae) and Neuromodulation (VNS Therapy for epilepsy and depression, plus OSA pipeline). Products are sold through direct sales and distributors in 100+ countries; the U.S. contributed 53%, Europe 19%, and Rest of World 28% of 2025 net revenue.